| Patented Medicine Prices Review Board Canada | news releases
Federal Minister of Health tables the 2017 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
New Patented Medicine Prices Review Board Chairperson announced
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the most recent edition of the Generics360 report, which examines the latest trends in domestic and international generic drug pricing, sales and utilization.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) today published a scoping paper which provides its initial thoughts on how best to operationalize the Minister of Health’s proposed amendments to the Patented Medicines Regulations, which were published in the Canada Gazette, Part I on December 2, 2017.
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Ginette Petitpas Taylor, Federal Minister of Health, yesterday tabled the 2016 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.
| Patented Medicine Prices Review Board Canada | backgrounders
The Honourable Ginette Petitpas Taylor, Federal Minister of Health, tabled the 2016 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate on October 26, 2017.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System research initiative, today published Alignment Among Public Formularies in Canada - Part 1: General Overview. This is the first report in a three-part series that compares drug coverage across provincial and federal public drug plans.
| Patented Medicine Prices Review Board Canada | news releases
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc.
| Patented Medicine Prices Review Board Canada | news releases
A new Patented Medicine Prices Review Board (PMPRB) report reveals that prescription drug expenditures by Canadian public drug plans reached $11.3 billion in 2015-16, up $1 billion over the previous year. This increase was mainly driven by a 12% growth in drug costs. While new and curative treatments for hepatitis C were major contributors to this growth, other high-cost drugs continued to put upward pressure on drug plans.
| Patented Medicine Prices Review Board Canada | statements
Patented Medicine Prices Review Board (PMPRB) Vice-chairperson Dr. Mitchell Levine today made the following statement on the launch of Health Canada’s consultation on potential changes to the Patented Medicines Regulations:
